Home » Newsletters » BioWorld Science

BioWorld Science

May 29, 1997

View Archived Issues

Creative BioMolecules: Q1 1997 highlights

CytoTherapeutics: Q1 1997 highlights

Hybridon: Q1 1997 highlights

Flamel Technologies: Report to investors at Alex, Brown Health Care Conference

Cypros: Report to investors at Van Kasper & Co. Growth Stock Conference

Selective M3 antagonists from Banyu

Kyoto describes ACAT/lipid peroxidation inhibitors

Nissan Chem. reveals antiplatelet agents

Hayashibara discloses potent, broad-spectrum antitumor agents

Ono reports AGE inhibitors and antioxidants

Heat shock protein fragments for RA from Peptide Therapeutic

Taisho prepares inhibitors of the production of IL-1beta/IL-6

Activated Cell Therapy's immunotherapy for prostate cancer enters clinic

Alphagan introduced in the U.K.

U.K. introduction for Nasonex

Integrin recognition surface identified

Loxiglumide efficacy in GERD reported

Fujisawa's new agent for hepatic ischemia-reperfusion injury

Bristol-Myers Squibb strengthens R&D in the Czech Republic

Gen-Probe and bioMerieux sign nucleic acid probe diagnostic agreement

Lamivudine clinical results in HBV

Gastric roles of COX-1 and COX-2 debated at DDW

Pasteur Merieux Connaught launches combination vaccine with acellular component

News on gastric ulcer drugs reported at Digestive Disease Week

Vital to develop anticancer drug

NIH sponsors ProScript's research on novel malaria treatment

Oxigene signs agreement for combretastatin development

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 4, 2026.
University of Western Australia patents 5-HT2A/B modulators
BioWorld Science
University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...
Alceptor Therapeutics discovers new α2B-adrenoceptor agonists
BioWorld Science
Alceptor Therapeutics Inc. has patented new pyrazol-5-amine α2B-adrenoceptor agonists reported to be useful for the treatment of pain and hypertension.
EQ-504 is AhR agonist for ulcerative colitis, related disorders
BioWorld Science
Activating the aryl hydrocarbon receptor (AhR) in immune cells enhances anti-inflammatory pathways and limits pathogenic immune responses. Equillium Inc. has...
Quintuple GLP-1–GIP–PPAR agonist for obesity and diabetes control
BioWorld
A new molecule combines the action of two incretins, GLP-1 and GIP, hormones that regulate glucose and appetite, with lanifibranor, a triple agonist of peroxisome...